TriLink BioTechnologies, A Maravai LifeSciences Company, Announces Manufacturing Capabilities Expansion As mRNA Manufacturing 32,000-Square-Foot, cGMP-grade Facility Nears Completion
Portfolio Pulse from Benzinga Newsdesk
TriLink BioTechnologies is expanding its manufacturing capabilities with a new 32,000-square-foot, cGMP-grade facility nearing completion. This will boost the company's mRNA manufacturing capacity.
May 24, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maravai LifeSciences, the parent company of TriLink BioTechnologies, may benefit from the expansion of mRNA manufacturing capabilities as the new facility nears completion.
The expansion of TriLink BioTechnologies' manufacturing capabilities with a new cGMP-grade facility will increase the company's mRNA manufacturing capacity. As a subsidiary of Maravai LifeSciences (MRVI), this expansion may positively impact MRVI's stock price in the short term due to the increased production capacity and potential for higher revenues.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80